| Q93085644 | "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients |
| Q33573863 | A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity |
| Q38288125 | Accelerating immune reconstitution after hematopoietic stem cell transplantation |
| Q34273968 | Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. |
| Q37242561 | Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells |
| Q92764877 | Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR |
| Q39100204 | Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders |
| Q61817999 | Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation |
| Q52721827 | Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders. |
| Q40895824 | Adoptive T cell therapy for the treatment of viral infections |
| Q26782845 | Adoptive T-Cell Immunotherapy |
| Q42271011 | Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry |
| Q38172451 | Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors |
| Q27030863 | Adoptive cell therapies for glioblastoma |
| Q39044990 | Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine. |
| Q26795540 | Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors |
| Q29393780 | Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes |
| Q27324235 | Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice |
| Q50079881 | Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation |
| Q38224988 | Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia |
| Q38544740 | Antigen-specific T cell therapies for cancer |
| Q27028006 | Antiviral T-cell therapy |
| Q55315844 | Artificial Antigen Presenting Cells: An Off the Shelf Approach for Generation of Desirable T-Cell Populations for Broad Application of Adoptive Immunotherapy. |
| Q35591760 | Blood and marrow transplant clinical trials network state of the Science Symposium 2014 |
| Q40859295 | Broad spectrum antiviral T cells for viral complications after hematopoietic stem cell transplantation |
| Q91737659 | CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo |
| Q42181212 | CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers |
| Q38942459 | CMV-specific immune reconstitution following allogeneic stem cell transplantation |
| Q89669654 | Cellular Immunotherapy in Lymphoma: Beyond CART Cells |
| Q98735538 | Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation |
| Q52569021 | Cellular therapies: Day by day, all the way. |
| Q28271836 | Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses |
| Q40215048 | Characterizing the Cellular Immune Response to Parainfluenza Virus 3. |
| Q38787776 | Checkpoint inhibition and cellular immunotherapy in lymphoma |
| Q38822525 | Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science |
| Q35083003 | Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma |
| Q39272183 | Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective |
| Q92341814 | Clinical-scale production of Aspergillus-specific T cells for the treatment of invasive aspergillosis in the immunocompromised host |
| Q40504861 | Comparative Analysis of Clinical-Scale IFN-γ-Positive T-Cell Enrichment Using Partially and Fully Integrated Platforms |
| Q33820695 | Controlling cytomegalovirus: helping the immune system take the lead |
| Q26822376 | Cord blood graft engineering |
| Q49829282 | Current Status of Gene Engineering Cell Therapeutics |
| Q39016336 | Current Trends and Alternative Scenarios in EBV Research |
| Q38365044 | Cytomegalovirus-specific T-cell therapies: current status and future prospects |
| Q55322590 | DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models. |
| Q37426542 | Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation |
| Q56967496 | Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative Disease |
| Q92095447 | Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD |
| Q90289040 | Donor lymphocyte infusion for BK virus hemorrhagic cystitis and nephropathy: a case report |
| Q37390239 | Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation |
| Q40441016 | EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas |
| Q42256599 | EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. |
| Q39441281 | EBV-related lymphomas: new approaches to treatment |
| Q59351745 | EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation |
| Q42264347 | Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases |
| Q26799602 | Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients |
| Q39284101 | Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL). |
| Q33766995 | Engineering cord blood to improve engraftment after cord blood transplant |
| Q36334405 | Enhanced antitumor effect of combining chemotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes in mice with EBV-related non-Hodgkin's lymphoma |
| Q90208950 | Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to viral directed immunotherapy |
| Q26822550 | Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target |
| Q40073030 | Epstein-Barr Virus LMP1 Mediated Oncogenicity. |
| Q47547404 | Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency |
| Q89551910 | Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes |
| Q26861623 | Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant |
| Q92023502 | Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities |
| Q33456742 | Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease |
| Q34363238 | Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy |
| Q35591430 | Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells |
| Q39978862 | Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. |
| Q40590036 | Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes. |
| Q33410603 | Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation. |
| Q49969196 | How I diagnose and treat post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation |
| Q39097082 | Human immunity against EBV-lessons from the clinic. |
| Q38524036 | II. Challenges in the management of post-transplant lymphoproliferative disorder |
| Q38263108 | Immune-based therapies for childhood cancer. |
| Q41932831 | Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy |
| Q64100737 | Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors |
| Q38803361 | Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma |
| Q38778924 | Immunotherapy against cancer-related viruses |
| Q26745428 | Immunotherapy for head and neck cancer: latest developments and clinical potential |
| Q36968163 | Immunotherapy for pediatric leukemia |
| Q39382670 | Immunotherapy for transplantation-associated viral infections |
| Q35958223 | Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia |
| Q42265908 | Impact of T cell selection methods in the success of clinical adoptive immunotherapy |
| Q42222507 | In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. |
| Q90567346 | Infectious Complications Following Kidney Transplantation-A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota |
| Q43964931 | Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy |
| Q54214517 | Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients. |
| Q37263151 | Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study |
| Q64377135 | Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells |
| Q91813278 | Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease |
| Q35296850 | Lymph Node Flow Cytometry as a Prompt Recognition of Ultra Early Onset PTLD: A Successful Case of Rituximab Treatment |
| Q26782902 | Lymphoma Immunotherapy: Current Status |
| Q26745838 | Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines |
| Q96304945 | Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation |
| Q28085769 | Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies |
| Q97537238 | Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV-specific T cells |
| Q38312596 | Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells |
| Q36438304 | Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials |
| Q36962653 | Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation |
| Q37344050 | New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation |
| Q38406089 | New cell sources for T cell engineering and adoptive immunotherapy |
| Q55094448 | Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma. |
| Q38066860 | Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen |
| Q26777394 | Novel immunotherapies in lymphoid malignancies |
| Q40092234 | Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation |
| Q89927507 | Pathobiology and Treatment of Lymphomatoid Granulomatosis; A Rare EBV-Driven Disorder |
| Q49798727 | Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes. |
| Q48321203 | Pharmacotherapeutic Management of Pediatric Lymphoma. |
| Q47550219 | Posttransplant chimeric antigen receptor therapy |
| Q26866013 | Posttransplant lymphoproliferative disease after pediatric solid organ transplantation |
| Q26801365 | Preventing stem cell transplantation-associated viral infections using T-cell therapy |
| Q35104509 | Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells |
| Q64374711 | Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections |
| Q98156927 | Rapidly expanded partially HLA DRB1-matched fungus-specific T cells mediate in vitro and in vivo antifungal activity |
| Q28079823 | Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications |
| Q38789518 | Recent advances in T-cell immunotherapy for haematological malignancies |
| Q44150295 | Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab |
| Q92621798 | Releasing the concept of HLA-allele specific peptide anchors in viral infections: A non-canonical naturally presented human cytomegalovirus-derived HLA-A*24:02 restricted peptide drives exquisite immunogenicity |
| Q42258745 | Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the Europe |
| Q37012569 | Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation |
| Q57176933 | Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target |
| Q37316838 | Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant |
| Q91774706 | Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients |
| Q50104242 | Second Malignancies after Hematopoietic Stem Cell Transplantation |
| Q38768298 | Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections |
| Q61798868 | Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation |
| Q35068768 | Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins |
| Q42234959 | Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles |
| Q37058107 | T cells for viral infections after allogeneic hematopoietic stem cell transplant |
| Q26853345 | T lymphocytes targeting native receptors |
| Q90176790 | T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies |
| Q38514497 | T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells |
| Q36142522 | T-cell therapy for viral infections following transplantation: why stop at three viruses? |
| Q38026758 | T-cell therapy in the treatment of post-transplant lymphoproliferative disease |
| Q37319382 | Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities |
| Q41219311 | The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder |
| Q35477534 | The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation |
| Q89828865 | The efficacy and safety of Epstein-Barr virus-specific antigen peptide-activated cytotoxic T-cells treatment for refractory or recurrent angioimmunoblastic T-cell lymphoma: A prospective clinical observational study |
| Q58724946 | The polymorphism at residue 156 determines the HLA-B*35 restricted peptide repertoire during HCMV infection |
| Q37592177 | The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care |
| Q92735537 | Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction |
| Q27313856 | Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. |
| Q33633262 | Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood |
| Q48640926 | Treating hematological malignancies with cell therapy: where are we now? |
| Q38797660 | Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. |
| Q38514503 | Umbilical cord blood graft engineering: challenges and opportunities. |
| Q38188591 | Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies |
| Q47603836 | Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT. |
| Q98291353 | Virus-Specific T Cell Therapies for HIV: Lessons Learned From Hematopoietic Stem Cell Transplantation |
| Q42654381 | Virus-Specific T Cells for the Immunocompromised Patient |
| Q64375296 | Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders |
| Q38797555 | Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections |
| Q54326551 | [Advances on Epstein-Barr virus related post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation]. |
| Q89021648 | [EBV related post-transplantation lymphoproliferative diseases in patients with severe aplastic anemia after allogeneic hematopoietic stem cell transplantation: five cases report and literatures review] |
Search more.